Lars Wortmann

Lars Wortmann is a Medicinal Chemist with more than 20 years of experience in industry (Boehringer Ingelheim GmbH & Co. KG, Bayer AG, Schering AG) with a particular focus on cardiometabolic diseases, obesity, oncology, gynocological diseases and contraception. A few projects resulted in the discovery of clinical candidates (ATR inhibitor, DGK alpha inhibitor, SOS1 inhibitor).

In addition, Lars supports Open Science and made several chemical probes available to the scientific community (e.g. modulators for HSD17B13, SOS1, PIP4K2A, ERK5, LHCG).

Lars studied chemistry at the University of Frankfurt (Diploma) and Aachen (Dr. rer. nat.) and performed postdoctoral studies at Stanford University.